Skip to main navigation
Skip to search
Skip to main content
Experts@Minnesota Home
Search content at Experts@Minnesota
Home
Profiles
Research units
University Assets
Projects and Grants
Research output
Datasets
Press/Media
Activities
Fellowships, Honors, and Prizes
Impacts
Clinical characteristics of post-transplant lymphoproliferative disorders
Vicki A Morrison
, David L. Dunn
, J. Carlos Manivel
, K. J. Gajl-Peczalska
, Bruce A Peterson
Medicine - Veteran's Administration Medical Center
Medicine - Hematology, Oncology, Transplant
Research output
:
Contribution to journal
›
Article
›
peer-review
229
Link opens in a new tab
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Clinical characteristics of post-transplant lymphoproliferative disorders'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Clinical Characteristics
100%
Lymphoproliferative Disorders
100%
Post-transplant Lymphoproliferative Disorder
100%
Immunosuppression
50%
Solid Organ Transplant
50%
Lymphoma
50%
B Cells
50%
Patient Outcomes
50%
Complete Remission
50%
Acyclovir
50%
Lung
25%
Therapeutic Approaches
25%
Liver
25%
Cyclosporine
25%
Prednisone
25%
Clinical Course
25%
Transplantation
25%
High Dose
25%
Chemotherapy
25%
Kidney
25%
Marrow
25%
Systemic Therapy
25%
Malignant T Cells
25%
Central Nervous System
25%
Heart-lung
25%
Interferon-α (IFN-α)
25%
Therapeutic Efficacy
25%
Combination Chemotherapy
25%
Clinical Treatment
25%
Course Outcomes
25%
Antilymphocyte Globulin
25%
Disease-free
25%
Immunophenotyping
25%
Surgical Excision
25%
Pathological Findings
25%
Stage I Disease
25%
Localized Disease
25%
New Therapeutic Approaches
25%
Extensive Disease
25%
Lymphoid Hyperplasia
25%
Solid Organ Transplantation
25%
Working Formulation
25%
Remission Duration
25%
Involved-field Radiotherapy
25%
Ann Arbor Staging System
25%
Medicine and Dentistry
Posttransplant Lymphoproliferative Disease
100%
Lymphoproliferative Disease
100%
Diseases
75%
B Cell
50%
Lung
50%
Immunosuppressive Treatment
50%
Aciclovir
50%
T Cell
25%
Drug Megadose
25%
Central Nervous System
25%
Disease Course
25%
Cyclosporine
25%
Systemic Therapy
25%
Azathioprine
25%
Combination Chemotherapy
25%
Solid Organ Transplantation
25%
Localized Disease
25%
Lymphocyte Antibody
25%
Interferon Alfa
25%
Involved-Field Radiotherapy
25%
Lymphoid Hyperplasia
25%
Ann Arbor Staging
25%
Prednisone
25%
Immunophenotyping
25%
Chemotherapy
25%
Pharmacology, Toxicology and Pharmaceutical Science
Lymphoproliferative Disease
100%
Posttransplant Lymphoproliferative Disease
100%
Diseases
100%
Remission
75%
Chemotherapy Regimens
50%
Aciclovir
50%
Ciclosporin
25%
Immunoglobulin
25%
Alpha Interferon
25%
Azathioprine
25%
Disease Course
25%
Lymphocyte Antibody
25%
Prednisone
25%
Lymphoid Hyperplasia
25%